PRL offers good results for high myopia

Article

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia.

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia, according to Esther Arranz-Marquez and co-workers from Vissum Corporación Oftalmológica de Madrid, Spain.

In a prospective study, the PRL was implanted in 78 myopic eyes in which the refractive error ranged between -4.0 and -31.0 D and laser refractive surgery was contraindicated. Uncorrected and best corrected visual acuity (UCVA & BCVA), manifest and cycloplegic refractions and intraocular pressure (IOP) were assessed over a three-year follow-up period.

The results revealed a significant change in spherical equivalent from a preoperative mean value of -14.7±5.4 D to 0±0.8 D three years postoperatively (p<0.01). UCVA and BCVA also improved significantly (p<0.01). Although a significant increase in IOP was found at each postoperative visit (p<0.01), there was no significant difference in IOP between one and three years postoperatively. Four eyes were operated on again due to mild lens decentration.

It was concluded that implantation of a PRL can offer good and predictable results for the correction of high myopia.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.